GeneDx Holdings Corp. (WGS) Stock Forecast
WGS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.88 / 5 from 8 analysts
- Price target
- $93.50 average of analyst targets
- Upside to target
- +47.0% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $0.07
- 52-week range
- $34.51 – $167.51
WGS analyst ratings
8 analystsNumber of analysts at each rating.
WGS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
WGS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.07 | $0.07 | $0.08 | $0.49 | −85.1% | 7 |
| Current fiscal year (2026) | $0.13 | $0.02 | $0.32 | $1.40 | −90.6% | 7 |
| Next fiscal year (2027) | $1.20 | $0.44 | $2.00 | $0.13 | +812.0% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
WGS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $122.9M | $122.1M | $124.3M | +5.3% | 8 |
| Current fiscal year (2026) | $481.8M | $478.0M | $484.3M | +12.7% | 9 |
| Next fiscal year (2027) | $599.0M | $574.4M | $626.4M | +24.3% | 8 |
WGS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
WGS revenue: reported and forecast
WGS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.10 | $0.07 | $0.07 | $0.07 | $0.07 | −28.9% | 1 up · 7 down |
| Current fiscal year (2026) | −$0.06 | $0.13 | $0.13 | $0.13 | $0.13 | −306.0% | 3 up · 2 down |
| Next fiscal year (2027) | $1.10 | $1.17 | $1.17 | $1.20 | $1.20 | +8.6% | 5 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
WGS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; WGS beat in 11 of 12.
What analysts expect from WGS
8 analysts cover GeneDx; their consensus rating is strong buy (4.88 on a 1–5 scale, where 5 is a strong buy). The average price target is $93.50, 47.0% above the latest close of $63.61. Analysts expect earnings of $0.13 per share for 2026, −90.6% from a year earlier. For 2027 the average estimate is $1.20 per share on revenue of $599.0 million. GeneDx beat the EPS estimate in 11 of the last 12 quarters.
Related: WGS income statement, WGS key metrics, WGS chart. See the WGS stock overview for the latest quote and news.
WGS forecast FAQ
What is GeneDx's price target?
The average analyst price target for GeneDx is $93.50, 47.0% above the latest close of $63.61.
Is GeneDx a buy, hold or sell?
Of 8 analysts covering GeneDx, 7 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is GeneDx's EPS forecast?
Analysts forecast $0.13 per share for 2026 (range $0.02 to $0.32); for 2027 the estimate is $1.20.
What is GeneDx's revenue forecast?
The average revenue estimate for 2026 is $481.8 million, growth of 12.7%; for 2027 it is $599.0 million.
When does GeneDx report earnings?
GeneDx is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes; the EPS estimate is $0.07.
Does GeneDx usually beat earnings estimates?
GeneDx reported EPS at or above the analyst estimate in 11 of the last 12 quarters.